Skip to content

AOCI at other companies

Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$415K-353%
Arrowhead Research logo
Arrowhead ResearchARWR
$742K-83.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$8K
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
-$1.62M-516%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-$767K-212%
Revvity logo
RevvityRVTY
-$253.56M+19.9%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%
Enterprise value$5.69B+69.8%
P/S1,298.3×+1,208×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's AOCI?
CRISPR Therapeutics (CRSP) reported AOCI of -$1.94M in Q1 2026.
How has CRISPR Therapeutics's AOCI changed year-over-year?
CRISPR Therapeutics's AOCI decreased by 146.9% year-over-year, from $4.14M to -$1.94M.
What is the long-term trend for CRISPR Therapeutics's AOCI?
Over 5 years (2020 to 2025), CRISPR Therapeutics's AOCI has grown at a 125.3% compound annual growth rate (CAGR), from -$83K to $4.82M.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.